GT Biopharma, Inc.
GTBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $6 | $9 | $10 |
| G&A Expenses | $0 | $0 | $0 | $48 |
| SG&A Expenses | $9 | $7 | $12 | $48 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $14 | $21 | $58 |
| Operating Income | -$14 | -$14 | -$21 | -$58 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $6 | $0 | -$0 |
| Pre-Tax Income | -$13 | -$8 | -$21 | -$58 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13 | -$8 | -$21 | -$58 |
| % Margin | – | – | – | – |
| EPS | -6.94 | -5.64 | -0.66 | -2.06 |
| % Growth | -23% | -754.5% | 68% | – |
| EPS Diluted | -6.94 | -5.64 | -0.66 | -2.06 |
| Weighted Avg Shares Out | 2 | 1 | 32 | 28 |
| Weighted Avg Shares Out Dil | 2 | 1 | 32 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $14 | $0 | $0 |
| EBITDA | -$13 | $6 | -$21 | -$57 |
| % Margin | – | – | – | – |